New hope for tough ovarian cancer: CBX-12 trial launches

NCT ID NCT06315491

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 32 times

Summary

This study tests a new drug called CBX-12 in 40 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the drug can shrink tumors and to check its safety at two different dose levels. Participants receive the drug once every 21 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Albert Einstein College of Medicine Montefiore Medical

    ACTIVE_NOT_RECRUITING

    New York, New York, 10021, United States

  • Allegheny Singer Research Institute D/B/A Ahn Research Institution

    RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

    Contact Phone: •••-•••-••••

  • Arizona Oncology Associates

    ACTIVE_NOT_RECRUITING

    Tucson, Arizona, 85711, United States

  • D&H Cancer Research Center

    ACTIVE_NOT_RECRUITING

    Margate, Florida, 33063, United States

  • Honor Health

    WITHDRAWN

    Scottsdale, Arizona, 85260, United States

  • Mary Crowley Cancer Research

    RECRUITING

    Dallas, Texas, 75251, United States

    Contact Phone: •••-•••-••••

  • Multicare Institute For Research & Innovation

    ACTIVE_NOT_RECRUITING

    Tacoma, Washington, 98405, United States

  • Northwest Cancer Centers

    WITHDRAWN

    Dyer, Indiana, 46311, United States

  • Norton Cancer Institute

    ACTIVE_NOT_RECRUITING

    Louisville, Kentucky, 40202, United States

  • Oncology Associates of Oregon

    ACTIVE_NOT_RECRUITING

    Eugene, Oregon, 97401, United States

  • Pci Nyu Langone Health

    ACTIVE_NOT_RECRUITING

    New York, New York, 10016, United States

  • South Florida Gynecology

    ACTIVE_NOT_RECRUITING

    Tampa, Florida, 33606, United States

  • Texas Oncology- Gulf Coast

    ACTIVE_NOT_RECRUITING

    The Woodlands, Texas, 77380, United States

  • University Hospitals Seidman Cancer Center

    ACTIVE_NOT_RECRUITING

    Cleveland, Ohio, 44106, United States

  • Usc Norris Comprehensive Cancer Center

    ACTIVE_NOT_RECRUITING

    Los Angeles, California, 90033, United States

  • Women's Cancer Care

    ACTIVE_NOT_RECRUITING

    Covington, Louisiana, 70433, United States

  • Yale University School of Medicine

    ACTIVE_NOT_RECRUITING

    New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.